Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flutiform versus Symbicort in moderate to severe persistent reversible asthma
2009-017223-25Phase 3Completed
- Sponsor
- Mundipharma
- Start
- Jan 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate + formoterol and budesonide in asthma (2 arms), sponsored by Mundipharma. Primary endpoint: Change in pre-morning dose FEV1 from baseline to end of treatment. Started Jan 2010; status: completed.
02
Drugs
fluticasone propionate + formoterolbudesonide
03
Conditions
asthma
Beyond the preview
Go deeper on 2009-017223-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017223-25.